Page 1

Aurinia Exhibit 99.1 AURINIA REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS - Quarter highlights include FDA approval , launch and early market penetration of LUPKYNIST as the first approved oral therapy for lupus nephritis ( LN ) - - -Over 250 patient start forms received by the end of the first quarter - Cash and cash equivalents , and investments of $ 360.9 million at March 31 , 2021- - Conference call to be hosted today at 5:00 p.m. ET - VICTORIA , British Columbia - May 6 , 2021 - Aurinia Pharmaceuticals Inc. ( NASDAQ : AUPH / TSX : AUP ) ( “ Aurinia ” or the “ Company ” ) today issued its financial results for the first quarter ended March 31 , 2021. Amounts , unless specified otherwise , are expressed in U.S. dollars . " 2021 started with the FDA approval of LUPKYNIS , the first FDA - approved oral treatment for active lupus nephritis - a devastating complication of lupus , " commented Peter Greenleaf , President and Chief Executive Officer of Aurinia . “ Our pivotal decision and work to build a world - class commercial infrastructure prior to approval ultimately led to Aurinia being able to make LUPKYNIS immediately available to patients and physicians following approval . Since that time , the Aurinia team has been encouraged by the feedback we are receiving from physicians and patients and our confidence has only grown as we continue to understand the tremendous need and value of LUPKYNIS , and work to accelerate broader adoption across the underserved LN population . " Recent Highlights FDA Approval and Commercial Launch of LUPKYNIS On January 22 , 2021 , the FDA approved LUPKYNIS in combination with a background immunosuppressive therapy regimen to treat adult patients with active LN . Commercial Activities • Engaged with over 6,000 rheumatologists and nephrologists ; • Received over 250 patient start forms during the first quarter ( covering 48 business days post - FDA approval ) ; • Converted nearly 40 % of patient start forms to patients on therapy by the end of the first quarter ; and • Launched LUPKYNIS Patient Marketing Campaign , Focus on the Fight , in April 2021 . " Since launch , the commercial team has focused on educating their customers on the urgency needed in reducing proteinuria for patients with active LN . With more than 250 patient start forms and 40 % of those patients on therapy after the first two months on the market , more than 6,000 clinical interactions , continued gradual expansion of payor coverage , and our Aurinia Alliance patient support program fully operational , the LUPKYNIS trajectory is on track against our internal projections . Furthermore , we anticipate that our market access will continue to improve as the rate of COVID vaccinations in the United States continues to climb and healthcare centers re - open their doors to patients , ” commented Max Colao , Chief Commercial Officer at Aurinia . 1